Pharmacological options for treatment of hyperandrogenic disorders.
Hyperandrogenic disorders are frequent in women. The most common cause is polycystic ovary syndrome, a condition found up to 7% in women of reproductive age. The effects of testosterone and dihydrotestosterone are elicited via androgen receptors. Androgen receptor acts as a ligand-dependent transcription factor that regulates the expression of several target genes. There are several pharmacological possibilities for the treatment of androgen excess, as inhibition of the biologic activity of androgens can be carried out at different levels. The androgen receptor, the 5alpha-reductase enzyme, and the hypothalamic-pituitary-gonad axis are the most frequent targets of antiandrogenic therapies. This review summarizes the structural and chemical features of currently available antiandrogenic drugs, including cyproterone acetate, spironolactone, flutamide and finasteride. Also, it presents some recent advances in the chemistry and pharmacology of novel steroidal and non-steroidal antiandrogens, and 5alpha-reductase inhibitors. Finally, recent knowledge on non-classical antiandrogenic drugs, such as insulin-sensitizers, ketoconazole, and GnRH-agonists are briefly discussed.
Reismann
P
P
2nd Department of Medicine, Faculty of Medicine, Semmelweis University, Budapest, H-1088 Hungary.
Likó
I
I
Igaz
P
P
Patócs
A
A
Rácz
K
K
D000726:Androgen Antagonists / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D059002:Androgen Receptor Antagonists; D000728:Androgens / Q000378:metabolism; D000818:Animals; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005260:Female; D006801:Humans; D017588:Hyperandrogenism / Q000188:drug therapy*; D008958:Models, Molecular; D011944:Receptors, Androgen / Q000737:chemistry / Q000378:metabolism
D000726:Androgen Antagonists; D059002:Androgen Receptor Antagonists; D000728:Androgens; D011944:Receptors, Androgen; D042944:Cholestenone 5 alpha-Reductase